Skip to content
Genentech
-
Genentech signs US$1.5B Earendil deal to develop AI-designed bispecific antibodies
Earendil, a biotechnology company operating in the US and China, will identify and develop bispecific antibody programmes based on target combinations agreed with Genentech.
-
Hanmi Pharm licenses obesity drug candidate HM17321 to Roche’s Genentech in US$2.3B deal
Hanmi is developing the HM17321 therapy as a potential first-in-class treatment that could promote weight loss while helping preserve lean body mass.
-
Roche to invest US$750M in new injectable manufacturing facility in Oregon
Construction of the Hillsboro facility is expected to create about 200 jobs, with workers remaining on site through the project’s anticipated completion in 2031.
-
SanegeneBio signs USD1.5B licensing agreement with Genentech for its RNAi therapy platform
The deal centers on one of SanegeneBio’s innovative RNAi programs and grants Genentech exclusive worldwide rights to develop and bring the treatment to market.